Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease

Biochemical Pharmacology

Volumn 97, Issue 4, 2015, Pages 399-407

  Quik, Maryka ^a   Zhang, Danhui ^a   McGregor, Matthew ^a   Bordia, Tanuja ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

Alpha7; L dopa induced dyskinesias; Neuroprotection; Nicotinic receptors; Parkinson s disease

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; ANISODAMINE; BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR AGONIST; DONEPEZIL; GALANTAMINE; LEVODOPA; NEOSTIGMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BETA2 AGONIST; POZANICLINE; TC 1698; TC 8831; UNCLASSIFIED DRUG; VARENICLINE; ANTIPARKINSON AGENT;

DRUG MECHANISM; DRUG TARGETING; HUMAN; LEVODOPA-INDUCED DYSKINESIA; MACACA FASCICULARIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SAIMIRI SCIUREUS; AGONISTS; METABOLISM;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANTIPARKINSON AGENTS; HUMANS; NICOTINIC AGONISTS; PARKINSON DISEASE;

EID: 84943356829     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.06.014     Document Type: Review

References (149)

1. J.M. Gorell, B.A. Rybicki, C.C. Johnson, and E.L. Peterson Smoking and Parkinson's disease: a dose-response relationship Neurology 52 1999 115 119
2. M.F. Allam, M.J. Campbell, A. Hofman, A.S. Del Castillo, and R. Fernandez-Crehuet Navajas Smoking and Parkinson's disease: systematic review of prospective studies Mov. Disord. 19 2004 614 621
3. A. Elbaz, and F. Moisan Update in the epidemiology of Parkinson's disease Curr. Opin. Neurol. 21 2008 454 460
4. A.J. Noyce, J.P. Bestwick, L. Silveira-Moriyama, C.H. Hawkes, G. Giovannoni, A.J. Lees, and et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease Ann. Neurol. 72 2012 893 901
5. C.M. Tanner Advances in environmental epidemiology Mov. Disord. 25 Suppl. 1 2010 S58 S62
6. K. Wirdefeldt, H.O. Adami, P. Cole, D. Trichopoulos, and J. Mandel Epidemiology and etiology of Parkinson's disease: a review of the evidence Eur. J. Epidemiol. 26 Suppl. 1 2011 S1 S58
7. E.L. Thacker, E.J. O'Reilly, M.G. Weisskopf, H. Chen, M.A. Schwarzschild, M.L. McCullough, and et al. Temporal relationship between cigarette smoking and risk of Parkinson disease Neurology 68 2007 764 768
8. E.J. O'Reilly, M.L. McCullough, A. Chao, S.J. Henley, E.E. Calle, M.J. Thun, and et al. Smokeless tobacco use and the risk of Parkinson's disease mortality Mov. Disord. 20 2005 1383 1384
9. S. Searles Nielsen, L.G. Gallagher, J.I. Lundin, W.T. Longstreth Jr., T. Smith-Weller, G.M. Franklin, and et al. Environmental tobacco smoke and Parkinson's disease Mov. Disord. 27 2012 293 296
10. B. Ritz, A. Ascherio, H. Checkoway, K.S. Marder, L.M. Nelson, W.A. Rocca, and et al. Pooled analysis of tobacco use and risk of Parkinson disease Arch. Neurol. 64 2007 990 997
11. C.M. Tanner, S.M. Goldman, D.A. Aston, R. Ottman, J. Ellenberg, R. Mayeux, and et al. Smoking and Parkinson's disease in twins Neurology 58 2002 581 588
12. B. Ritz, P.C. Lee, C.F. Lassen, and O.A. Arah Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease Neurology 2014
13. C. Rapier, G.G. Lunt, and S. Wonnacott Nicotinic modulation of [3H]dopamine release from striatal synaptosomes: pharmacological characterisation J. Neurochem. 54 1990 937 945
14. W. Lichtensteiger, F. Hefti, D. Felix, T. Huwyler, E. Melamed, and M. Schlumpf Stimulation of nigrostriatal dopamine neurones by nicotine Neuropharmacology 21 1982 963 968
15. T.C. Westfall, M.J. Besson, M.F. Giorguieff, and J. Glowinski The role of presynaptic receptors in the release and synthesis of 3H-dopamine by slices of rat striatum Naunyn Schmiedebergs Arch. Pharmacol. 292 1976 279 287
16. M.F. Giorguieff, M.L. Le Floc'h, T.C. Westfall, J. Glowinski, and M.J. Besson Nicotinic effect of acetylcholine on the release of newly synthesized (3H)dopamine in rat striatal slices and cat caudate nucleus Brain Res. 106 1976 117 131
17. N.S. Millar, and C. Gotti Diversity of vertebrate nicotinic acetylcholine receptors Neuropharmacology 56 2009 237 246
18. E.X. Albuquerque, E.F. Pereira, M. Alkondon, and S.W. Rogers Mammalian nicotinic acetylcholine receptors: from structure to function Physiol. Rev. 89 2009 73 120
19. M. Quik, and S. Wonnacott {alpha}6{beta}2∗and {alpha}4{beta}2∗nicotinic acetylcholine receptors as drug targets for Parkinson's disease Pharmacol. Rev. 63 2011 938 966
20. C.P. Fenster, M.F. Rains, B. Noerager, M.W. Quick, and R.A. Lester Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine J. Neurosci. 17 1997 5747 5759
21. J.X. Shen, and J.L. Yakel Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system Acta Pharmacol. Sin. 30 2009 673 680
22. D.K. Berg, and W.G. Conroy Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons J. Neurobiol. 53 2002 512 523
23. J.R. Pauly, J.A. Stitzel, M.J. Marks, and A.C. Collins An autoradiographic analysis of cholinergic receptors in mouse brain Brain Res. Bull. 22 1989 453 459
24. M.J. Marks, J.R. Pauly, E.U. Grun, and A.C. Collins ST/b and DBA/2 mice differ in brain alpha-bungarotoxin binding and alpha 7 nicotinic receptor subunit mRNA levels: a quantitative autoradiographic analysis Brain Res. Mol. Brain Res. 39 1996 207 222
25. S. Hunt, and J. Schmidt Some observations on the binding patterns of alpha-bungarotoxin in the central nervous system of the rat Brain Res. 157 1978 213 232
26. C.R. Breese, C. Adams, J. Logel, C. Drebing, Y. Rollins, M. Barnhart, and et al. Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain J. Comp. Neurol. 387 1997 385 398
27. Z.Y. Han, M. Zoli, A. Cardona, J.P. Bourgeois, J.P. Changeux, and N. Le Novere Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]alpha-bungarotoxin binding sites in the brain of Macaca mulatta J. Comp. Neurol. 461 2003 49 60
28. M. Quik, Y. Polonskaya, A. Gillespie, M. Jakowec, G.K. Lloyd, and J.W. Langston Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization J. Comp. Neurol. 425 2000 58 69
29. P.B. Clarke, R.D. Schwartz, S.M. Paul, C.B. Pert, and A. Pert Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin J. Neurosci. 5 1985 1307 1315
30. P.S. Olofsson, M. Rosas-Ballina, Y.A. Levine, and K.J. Tracey Rethinking inflammation: neural circuits in the regulation of immunity Immunol. Rev. 248 2012 188 204
31. M. Bencherif, S.T. Narla, and M.S. Stachowiak Alpha7 neuronal nicotinic receptor: a pluripotent target for diseases of the central nervous system CNS Neurol. Disord. Drug Targets 13 2014 836 845
32. R. Freedman alpha7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia Annu. Rev. Med. 65 2014 245 261
33. K.T. Dineley, A.A. Pandya, and J.L. Yakel Nicotinic ACh receptors as therapeutic targets in CNS disorders Trends Pharmacol. Sci. 36 2015 96 108
34. M. Quik, D. Zhang, X.A. Perez, and T. Bordia Role for the nicotinic cholinergic system in movement disorders; therapeutic implications Pharmacol. Ther. 144 2014 50 59
35. N.L. Yohn, J.R. Turner, and J.A. Blendy Activation of alpha4beta2∗/alpha 6beta2∗nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors J. Pharmacol. Exp. Ther. 349 2014 348 354
36. M.L. Kelso, and J.H. Oestreich Traumatic brain injury: central and peripheral role of alpha7 nicotinic acetylcholine receptors Curr. Drug Targets 13 2012 631 636
37. M. Quik, and S. Geertsen Neuronal nicotinic alpha-bungarotoxin sites Can. J. Physiol. Pharmacol. 66 1988 971 979
38. S.W. Halvorsen, and D.K. Berg Specific down-regulation of the alpha-bungarotoxin binding component on chick autonomic neurons by ciliary neuronotrophic factor J. Neurosci. 9 1989 3673 3680
39. V. Coronas, M. Durand, J.G. Chabot, F. Jourdan, and R. Quirion Acetylcholine induces neuritic outgrowth in rat primary olfactory bulb cultures Neuroscience 98 2000 213 219
40. S. Vijayaraghavan, P.C. Pugh, Z.W. Zhang, M.M. Rathouz, and D.K. Berg Nicotinic receptors that bind alpha-bungarotoxin on neurons raise intracellular free Ca2+ Neuron 8 1992 353 362
41. J. Chan, and M. Quik A role for the nicotinic alpha-bungarotoxin receptor in neurite outgrowth in PC12 cells Neuroscience 56 1993 441 451
42. R.S. Broide, R.T. Robertson, and F.M. Leslie Regulation of alpha7 nicotinic acetylcholine receptors in the developing rat somatosensory cortex by thalamocortical afferents J. Neurosci. 16 1996 2956 2971
43. V.B. Aramakis, and R. Metherate Nicotine selectively enhances NMDA receptor-mediated synaptic transmission during postnatal development in sensory neocortex J. Neurosci. 18 1998 8485 8495
44. W.M. Kaneko, L.R. Britto, J.M. Lindstrom, and H.J. Karten Distribution of the alpha7 nicotinic acetylcholine receptor subunit in the developing chick cerebellum Brain Res. Dev. Brain Res. 105 1998 141 145
45. R.S. Broide, and F.M. Leslie The alpha7 nicotinic acetylcholine receptor in neuronal plasticity Mol. Neurobiol. 20 1999 1 16
46. Y. Takada, A. Yonezawa, T. Kume, H. Katsuki, S. Kaneko, H. Sugimoto, and et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons J. Pharmacol. Exp. Ther. 306 2003 772 777
47. T. Kihara, S. Shimohama, H. Sawada, J. Kimura, T. Kume, H. Kochiyama, and et al. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity Ann. Neurol. 42 1997 159 163
48. T. Kihara, H. Sawada, T. Nakamizo, R. Kanki, H. Yamashita, A. Maelicke, and et al. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity Biochem. Biophys. Res. Commun. 325 2004 976 982
49. S. Kaneko, T. Maeda, T. Kume, H. Kochiyama, A. Akaike, S. Shimohama, and et al. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors Brain Res. 765 1997 135 140
50. Y. Li, M.A. King, J. Grimes, N. Smith, C.M. de Fiebre, and E.M. Meyer Alpha7 nicotinic receptor mediated protection against ethanol-induced cytotoxicity in PC12 cells Brain Res. 816 1999 225 228
51. T. Kihara, S. Shimohama, H. Sawada, K. Honda, T. Nakamizo, H. Shibasaki, and et al. alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity J. Biol. Chem. 276 2001 13541 13546
52. W. Yu, N. Mechawar, S. Krantic, and R. Quirion alpha7 Nicotinic receptor activation reduces beta-amyloid-induced apoptosis by inhibiting caspase-independent death through phosphatidylinositol 3-kinase signaling J. Neurochem. 119 2011 848 858
53. T. Nakamizo, J. Kawamata, H. Yamashita, R. Kanki, T. Kihara, H. Sawada, and et al. Stimulation of nicotinic acetylcholine receptors protects motor neurons Biochem. Biophys. Res. Commun. 330 2005 1285 1289
54. R.R. Jonnala, A.V. Terry Jr., and J.J. Buccafusco Nicotine increases the expression of high affinity nerve growth factor receptors in both in vitro and in vivo Life Sci. 70 2002 1543 1554
55. S. Shimohama, A. Akaike, and J. Kimura Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation Ann. N. Y. Acad. Sci. 777 1996 356 361
56. F.A. Dajas-Bailador, P.A. Lima, and S. Wonnacott The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism Neuropharmacology 39 2000 2799 2807
57. H. Shen, T. Kihara, H. Hongo, X. Wu, W.R. Kem, S. Shimohama, and et al. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors Br. J. Pharmacol. 161 2010 127 139
58. R.R. Jonnala, J.H. Graham 3rd, A.V. Terry Jr., J.W. Beach, J.A. Young, and J.J. Buccafusco Relative levels of cytoprotection produced by analogs of choline and the role of alpha7-nicotinic acetylcholine receptors Synapse (New York, NY) 47 2003 262 269
59. E. Arias, E. Ales, N.H. Gabilan, M.F. Cano-Abad, M. Villarroya, A.G. Garcia, and et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors Neuropharmacology 46 2004 103 114
60. Q. Li, D. Wu, L. Zhang, and Y. Zhang Effects of galantamine on beta-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells Exp. Gerontol. 45 2010 842 847
61. E. Parada, J. Egea, A. Romero, L. del Barrio, A.G. Garcia, and M.G. Lopez Poststress treatment with PNU282987 can rescue SH-SY5Y cells undergoing apoptosis via alpha7 nicotinic receptors linked to a Jak2/Akt/HO-1 signaling pathway Free Radic. Biol. Med. 49 2010 1815 1821
62. M.B. Marrero, R.L. Papke, B.S. Bhatti, S. Shaw, and M. Bencherif The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase J. Pharmacol. Exp. Ther. 309 2004 16 27
63. L. Del Barrio, M.D. Martin-de-Saavedra, A. Romero, E. Parada, J. Egea, J. Avila, and et al. Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by alpha7 and beta2∗nicotinic stimulation Toxicol. Sci. 123 2011 193 205
64. Y. Li, R.L. Papke, Y.J. He, W.J. Millard, and E.M. Meyer Characterization of the neuroprotective and toxic effects of alpha7 nicotinic receptor activation in PC12 cells Brain Res. 830 1999 218 225
65. Y. Li, E.M. Meyer, D.W. Walker, W.J. Millard, Y.J. He, and M.A. King Alpha7 nicotinic receptor activation inhibits ethanol-induced mitochondrial dysfunction, cytochrome c release and neurotoxicity in primary rat hippocampal neuronal cultures J. Neurochem. 81 2002 853 858
66. N.C. de Fiebre, and C.M. de Fiebre Alpha 7 nicotinic acetylcholine receptor-mediated protection against ethanol-induced neurotoxicity Alcohol 31 2003 149 153
67. X.Q. Ren, S.B. Cheng, M.W. Treuil, J. Mukherjee, J. Rao, K.H. Braunewell, and et al. Structural determinants of alpha4beta2 nicotinic acetylcholine receptor trafficking J. Neurosci. 25 2005 6676 6686
68. A.O. Rosa, J. Egea, L. Gandia, M.G. Lopez, and A.G. Garcia Neuroprotection by nicotine in hippocampal slices subjected to oxygen-glucose deprivation: involvement of the alpha7 nAChR subtype J. Mol. Neurosci. 30 2006 61 62
69. J. Egea, A.O. Rosa, M. Sobrado, L. Gandia, M.G. Lopez, and A.G. Garcia Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice Neuroscience 145 2007 866 872
70. L.C. Gahring, E.L. Meyer, and S.W. Rogers Nicotine-induced neuroprotection against N-methyl-d-aspartic acid or beta-amyloid peptide occur through independent mechanisms distinguished by pro-inflammatory cytokines J. Neurochem. 87 2003 1125 1136
71. J. Qian, J.M. Zhang, L.L. Lin, W.Z. Dong, Y.Q. Cheng, D.F. Su, and et al. A combination of neostigmine and anisodamine protects against ischemic stroke by activating alpha7nAChR Int. J. Stroke 2015
72. N.C. de Fiebre, and C.M. de Fiebre alpha7 Nicotinic acetylcholine receptor knockout selectively enhances ethanol-, but not beta-amyloid-induced neurotoxicity Neurosci. Lett. 373 2005 42 47
73. C.M. Hernandez, R. Kayed, H. Zheng, J.D. Sweatt, and K.T. Dineley Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease J. Neurosci. 30 2010 2442 2453
74. M.J. O'Neill, T.K. Murray, V. Lakics, N.P. Visanji, and S. Duty The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration Curr. Drug Target CNS Neurol. Disord. 1 2002 399 411
75. J. Kawamata, S. Suzuki, and S. Shimohama alpha7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease Curr. Drug Targets 13 2012 623 630
76. M. Quik, M. O'Neill, and X.A. Perez Nicotine neuroprotection against nigrostriatal damage: importance of the animal model Trends Pharmacol. Sci. 28 2007 229 235
77. A.M. Janson, K. Fuxe, L.F. Agnati, I. Kitayama, A. Harfstrand, K. Andersson, and et al. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection Brain Res. 455 1988 332 345
78. A.M. Janson, P.B. Hedlund, M. Hillefors, and G. von Euler Chronic nicotine treatment decreases dopamine D2 agonist binding in the rat basal ganglia Neuroreport 3 1992 1117 1120
79. A.M. Janson, J.J. Meana, M. Goiny, and M. Herrera-Marschitz Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study Neurosci. Lett. 134 1991 88 92
80. G. Costa, J.A. Abin-Carriquiry, and F. Dajas Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra Brain Res. 888 2001 336 342
81. R.E. Ryan, S.A. Ross, J. Drago, and R.E. Loiacono Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice Br. J. Pharmacol. 132 2001 1650 1656
82. N.P. Visanji, S.H. Fox, T. Johnston, G. Reyes, M.J. Millan, and J.M. Brotchie Dopamine D(3) receptor stimulation underlies the development of l-DOPA-induced dyskinesia in animal models of Parkinson's disease Neurobiol. Dis. 35 2008 184 192
83. R. Soto-Otero, E. Mendez-Alvarez, A. Hermida-Ameijeiras, A.M. Lopez-Real, and J.L. Labandeira-Garcia Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease Biochem. Pharmacol. 64 2002 125 135
84. K. Parain, V. Marchand, B. Dumery, and E. Hirsch Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice Brain Res. 890 2001 347 350
85. A.M. Janson, K. Fuxe, L. Agnati, E. Sundstrom, and M. Goldstein The effect of chronic nicotine treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degneration of nigrostriatal dopamine neurons in the black mouse Adv. Pharmacol. Sci. 1 1991 323 329
86. R.A. Behmand, and S.I. Harik Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity J. Neurochem. 58 1992 776 779
87. H. Sershen, A. Hashim, H.L. Wiener, and A. Lajtha Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse Neurosci. Lett. 93 1988 270 274
88. M. Hadjiconstantinou, J.P. Hubble, T.A. Wemlinger, and N.H. Neff Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists J. Pharmacol. Exp. Ther. 270 1994 639 644
89. M. Quik, L. Chen, N. Parameswaran, X. Xie, J.W. Langston, and S.E. McCallum Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates J. Neurosci. 26 2006 4681 4689
90. M. Quik, N. Parameswaran, S.E. McCallum, T. Bordia, S. Bao, A. McCormack, and et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates J. Neurochem. 98 2006 1866 1875
91. T. Bordia, M.W. Decker, M. Quik, Unpublished observation.
92. R. Srinivasan, C.I. Richards, C. Xiao, D. Rhee, R. Pantoja, D.A. Dougherty, and et al. Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response Mol. Pharmacol. 81 2012 759 769
93. R. Srinivasan, R. Pantoja, F.J. Moss, E.D. Mackey, C.D. Son, J. Miwa, and et al. Nicotine up-regulates {alpha}4{beta}2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning J. Gen. Physiol. 137 2011 59 79
94. S. Shimohama Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models Biol. Pharm. Bull. 32 2009 332 336
95. T. Bordia, M. McGregor, R.L. Papke, M.W. Decker, J.M. McIntosh, and M. Quik The alpha7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions Exp. Neurol. 263 2015 277 284
96. S. Suzuki, J. Kawamata, T. Matsushita, A. Matsumura, S. Hisahara, K. Takata, and et al. 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through alpha7 nicotinic acetylcholine receptor stimulation in rats J. Neurosci. Res. 91 2013 462 471
97. T. Yanagida, H. Takeuchi, Y. Kitamura, K. Takata, H. Minamino, T. Shibaike, and et al. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model Neurosci. Res. 62 2008 254 261
98. V. Stuckenholz, M. Bacher, M. Balzer-Geldsetzer, D. Alvarez-Fischer, W.H. Oertel, R.C. Dodel, and et al. The alpha7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice J. Parkinsons Dis. 3 2013 161 172
99. Y. Liu, J. Hu, J. Wu, C. Zhu, Y. Hui, Y. Han, and et al. alpha7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation J. Neuroinflammation 9 2012 98
100. R. Pahwa, and K.E. Lyons Treatment of early Parkinson's disease Curr. Opin. Neurol. 27 2014 442 449
101. A.C. Vijverman, and S.H. Fox New treatments for the motor symptoms of Parkinson's disease Expert Rev. Clin. Pharmacol. 7 2014 761 777
102. R. Heumann, R. Moratalla, M.T. Herrero, K. Chakrabarty, R. Drucker-Colin, J.R. Garcia-Montes, and et al. Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions J. Neurochem. 130 2014 472 489
103. B.S. Connolly, and A.E. Lang Pharmacological treatment of Parkinson disease: a review JAMA 311 2014 1670 1683
104. R. Pahwa, C.M. Tanner, R.A. Hauser, K. Sethi, S. Isaacson, D. Truong, and et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study) Mov. Disord. 30 2015 788 795
105. E. Schaeffer, A. Pilotto, and D. Berg Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's Disease CNS Drugs 28 2014 1155 1184
106. M. Quik, H. Cox, N. Parameswaran, K. O'Leary, J.W. Langston, and D. Di Monte Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys Ann. Neurol. 62 2007 588 596
107. M. Quik, A. Mallela, M. Chin, J.M. McIntosh, X.A. Perez, and T. Bordia Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function Neurobiol. Dis. 50 2013 30 41
108. M. Quik, A. Mallela, J. Ly, and D. Zhang Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease Mov. Disord. 28 2013 1398 1406
109. T. Bordia, C. Campos, J.M. McIntosh, and M. Quik Nicotinic receptor-mediated reduction in l-dopa-induced dyskinesias may occur via desensitization J. Pharmacol. Exp. Ther. 333 2010 929 938
110. T. Bordia, C. Campos, L. Huang, and M. Quik Continuous and intermittent nicotine treatment reduces l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson's disease J. Pharmacol. Exp. Ther. 327 2008 239 247
111. L. Huang, S.R. Grady, and M. Quik Nicotine reduces l-dopa-induced dyskinesias by acting at {beta}2 nicotinic receptors J. Pharmacol. Exp. Ther. 338 2011 932 941
112. K.B. Mihalak, F.I. Carroll, and C.W. Luetje Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors Mol. Pharmacol. 70 2006 801 805
113. T. Bordia, F.I. Carroll, and M. Quik Varenicline markedly decreases antipsychotic-induced tardive dyskinesia in a rodent model Soc. Neurosci. Abstr. 33 2013 32.07
114. H. Ween, K. Thorin-Hagene, E. Andersen, J.H. Gronlien, C.H. Lee, M. Gopalakrishnan, and et al. alpha3∗and alpha7 nAChR-mediated Ca(2+) transient generation in IMR-32 neuroblastoma cells Neurochem. Int. 57 2010 269 277
115. D. Zhang, A. Mallela, D. Sohn, F.I. Carroll, M. Bencherif, S. Letchworth, and et al. Nicotinic receptor agonists reduce l-DOPA-induced dyskinesias in a monkey model of Parkinson's disease J. Pharmacol. Exp. Ther. 347 2013 225 234
116. M. Quik, C. Campos, and S.R. Grady Multiple CNS nicotinic receptors mediate l-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice Biochem. Pharmacol. 86 2013 1153 1162
117. D. Zhang, M. McGregor, T. Bordia, X. Perez, M.W. Decker, and M. Quik The alpha7 nicotinic receptor agonist ABT-126 decreases l-Dopa-induced dyskinesias in MPTP-lesioned monkeys Soc. Neurosci. Abstr. 2015
118. T. Di Paolo, L. Gregoire, D. Feuerbach, W. Elbast, M. Weiss, and B. Gomez-Mancilla AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys Parkinsonism Relat. Disord. 20 2014 1119 1123
119. T.H. Johnston, P. Huot, S.H. Fox, J.B. Koprich, K.T. Szeliga, J.W. James, and et al. TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque Neuropharmacology 73 2013 337 347
120. D. Zhang, A. Mallela, F.I. Carroll, M. Quik, Nicotinic receptor agonists reduce l-dopa-induced dyskinesias in a monkey model of Parkinson's disease. Submitted, 2013.
121. J. Mather, Burdette, Cebers, Posener, Alexander, Leventer, and et al. Potential of AZD1446, a novel nicotinic agonist, for the treatment of l-DOPA-induced dyskinesia in Parkinson's disease Soc. Neurosci. Abstr. 43 2014 (137.11/L1)
122. D. Zhang, T. Bordia, M. McGregor, J.M. McIntosh, M.W. Decker, and M. Quik ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease Mov. Disord. 29 2014 508 517
123. R. Gray, A.S. Rajan, K.A. Radcliffe, M. Yakehiro, and J.A. Dani Hippocampal synaptic transmission enhanced by low concentrations of nicotine Nature 383 1996 713 716
124. P. Seguela, J. Wadiche, K. Dineley-Miller, J.A. Dani, and J.W. Patrick Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium J. Neurosci. 13 1993 596 604
125. S. Shimohama, and T. Kihara Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity Biol. Psychiatry. 49 2001 233 239
126. K. Ren, V. Puig, R.L. Papke, Y. Itoh, J.A. Hughes, and E.M. Meyer Multiple calcium channels and kinases mediate alpha7 nicotinic receptor neuroprotection in PC12 cells J. Neurochem. 94 2005 926 933
127. J. Arredondo, A.I. Chernyavsky, D.L. Jolkovsky, K.E. Pinkerton, and S.A. Grando Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes FASEB J. 20 2006 2093 2101
128. S. Shaw, M. Bencherif, and M.B. Marrero Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid J. Biol. Chem. 277 2002 44920 44924
129. M. Toborek, K.W. Son, A. Pudelko, K. King-Pospisil, E. Wylegala, and A. Malecki ERK 1/2 signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons J. Cell. Biochem. 100 2007 279 292
130. K. Ren, M.A. King, J. Liu, J. Siemann, M. Altman, C. Meyers, and et al. The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice Neuroscience 148 2007 230 237
131. E. Tyagi, R. Agrawal, C. Nath, and R. Shukla Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation Neurochem. Int. 56 2010 135 142
132. 2+ FASEB J. 25 2011 2563 2573
133. H. Takeuchi, T. Yanagida, M. Inden, K. Takata, Y. Kitamura, K. Yamakawa, and et al. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models J. Neurosci. Res. 87 2009 576 585
134. G. Sharma, and S. Vijayaraghavan Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores Proc. Natl. Acad. Sci. U. S. A. 98 2001 4148 4153
135. J.X. Shen, and J.L. Yakel Functional alpha7 nicotinic ACh receptors on astrocytes in rat hippocampal CA1 slices J. Mol. Neurosci. 48 2012 14 21
136. Y. Liu, X. Zeng, Y. Hui, C. Zhu, J. Wu, D.H. Taylor, and et al. Activation of alpha7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson's disease Neuropharmacology 91 2015 87 96
137. M.A. Cenci Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia Trends Neurosci. 30 2007 236 243
138. T. Bordia, J.M. McIntosh, and M. Quik The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release J. Neurochem. 125 2013 291 302
139. S. Kaiser, and S. Wonnacott alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release Mol. Pharmacol. 58 2000 312 318
140. R. Klink, A. de Kerchove d'Exaerde, M. Zoli, and J.P. Changeux Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei J. Neurosci. 21 2001 1452 1463
141. T. Fieblinger, and M.A. Cenci Zooming in on the small: the plasticity of striatal dendritic spines in l-DOPA-induced dyskinesia Mov. Disord. 30 2015 484 493
142. Y. Zhang, G.E. Meredith, N. Mendoza-Elias, D.J. Rademacher, K.Y. Tseng, and K. Steece-Collier Aberrant restoration of spines and their synapses in l-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses J. Neurosci. 33 2013 11655 11667
143. L.M. Suarez, O. Solis, J.M. Carames, I.R. Taravini, J.M. Solis, M.G. Murer, and et al. l-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice Biol. Psychiatry 75 2014 711 722
144. H. Nishijima, S. Suzuki, T. Kon, Y. Funamizu, T. Ueno, R. Haga, and et al. Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model Mov. Disord. 29 2014 336 343
145. P.C. Pugh, and D.K. Berg Neuronal acetylcholine receptors that bind alpha-bungarotoxin mediate neurite retraction in a calcium-dependent manner J. Neurosci. 14 1994 889 896
146. A.A. Othman, R.A. Lenz, J. Zhang, J. Li, W.M. Awni, and S. Dutta Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers J. Clin. Pharmacol. 51 2011 512 526
147. L. Gault, C.W. Ritchie, W.Z. Robieson, Y. Pritchett, A.A. Othman, and R.A. Lenz A phase 2 randomized, controlled trial of the 7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia Alzheimers Dementia 2015 (in press)
148. E. Arias, S. Gallego-Sandin, M. Villarroya, A.G. Garcia, and M.G. Lopez Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors J. Pharmacol. Exp. Ther. 315 2005 1346 1353
149. D. Zhang, M. McGregor, M.W. Decker, and M. Quik The alpha7 nicotinic receptor agonist ABT-107 decreases l-Dopa-induced dyskinesias in parkinsonian monkeys J. Pharmacol. Exp. Ther. 351 2014 25 32